Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases

Summary

The bill would let licensed physicians prescribe, and eligible hospitals administer, experimental drugs, biologics, or devices that have passed Phase 1 but are not yet FDA‑approved, for patients with terminal illnesses or life‑threatening rare diseases. It sets strict eligibility, informed‑consent, and oversight requirements and encourages insurers to cover these treatments. The measure failed, dying in a subcommittee.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share